Revision of WHO Guidelines for Treating Some HIV-infected Women Influenced by OCTANE Study

by Kathy Jones on  October 16, 2010 at 8:36 PM AIDS/HIV News
  •   Print
  •   Share
  •   Comments
  •  Text 
The World Health Organization (WHO) was infleunced to change its guidelines this year for the treatment of HIV-infected women who receive a single dose of the antiretroviral drug nevirapine to prevent HIV transmission to their babies by findings from a study, which appear in the Oct. 14, 2010 New England Journal of Medicine,.

The study demonstrated that the single dose of nevirapine used to prevent mother-to-child transmission of HIV can hamper the drug's effectiveness if it is also used later as part of a regimen to treat these same individuals.

The Phase III study, called Optimal Combination Therapy after Nevirapine Exposure (OCTANE), enrolled 745 women at 10 sites in seven African countries to address the critical question around nevirapine resistance. The drug nevirapine is inexpensive and accessible, and is widely used in resource-constrained settings for both treating HIV and preventing mother-to-child transmission (PMTCT).

The Adult AIDS Clinical Trials Group conducted the study with funding from the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health. The U.S. Military HIV Research Program's (MHRP) network site in Kericho, Kenya, the Kenya Medical Research Institute/Walter Reed Project, and another partner site in Eldoret, Kenya, participated in the study and enrolled 74 participants.

"This is very exciting news indeed!" said Dr. Fred Sawe, MHRP partner and the local principal investigator for the OCTANE study in Kericho. "We now have a definite answer to a problem that has continued to haunt us for the last 10 years. Given the infrastructure we have so far built in PMTCT programs, we can now minimize use of single dose only nevirapine-based interventions, increase access to more efficacious regimens, and provide better care to women who have been exposed to single-dose nevirapine without slowing down the progress of eliminating pediatric AIDS: a win-win situation of great public health importance."

Page 1 Page 1 | 2  Next
 Email Email   RSS Feeds RSS Feeds   Print this page Print   Save this page Save   Link Link   Syndicate Syndicate   Comments Comments   Bookmark and Share
 
Comment & Contribute
Comments should be on the topic and should not be abusive. Comments are normally moderated and are reviewed after they are posted.
* Your comment can be maximum of 2500 characters

Notify me when reply is posted
I agree to the terms and conditions
  
If you have a question about health related issues, you can now post it in our Ask An Expert section on our community website Medwonders.com and get answers from our panel of experts.
X

Medwonders Health Network

  • Health News Index
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
News Archive
Date :
Category :
Keyword :
  • News Quick Links
News Central Health Watch
Latest Health News Health In Focus
News Category (500+) Breaking Health News
Popular News Celebrating Life
Health News and Press Release Medindia - Exclusive
News Photo Gallery India Special
News Video Gallery Lifestyle and Wellness
News From Other Resources
HIV
Complete Medindia Resources
News Categories:  
Diabetes Health Center

AIDS/HIV Related News

» Antibodies That Help to Stop HIV Virus Found in Breast Milk » Rectal Use of Reduced Glycerin Formulation of Tenofovir Vaginal Gel Deemed Safe
» Report Says Clergy can Fight HIV on Faith-Friendly Terms » HIV Epidemic may Afflict Nearly Half of Asia-Pacific Transgender People: UN
» 740,000 Lives Rescued With US AIDS Relief Program: Study » Include Behavioural Strategies in HIV Prevention Measures To Function: APA
» US Panel Urges Quick In-home HIV Test Approval » Funding Criminal Justice Reforms Key to Reducing Spread of HIV and TB in African Prisons
Read More >>